Paraoxonase genes and disease

Annals of Medicine

Volumn 31, Issue 3, 1999, Pages 217-224

  Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Lipoproteins; Organophosphates; Oxidation; Phospholipids

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GENE PRODUCT; MESSENGER RNA; PHOSPHOLIPID;

ARTICLE; ATHEROSCLEROSIS; BIRTH WEIGHT; CHROMOSOME 7Q; GENE EXPRESSION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032971881     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909115981     Document Type: Article

References (48)

1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/aryiesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498-509.
2. Tsui LC, Buchwald M, Barker D, Braman JC, Knowlton R, Schumm JW, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985; 230: 1054-7.
3. Mackness MI. Possible medical significance of human serum paraoxonase. In: Reiner E, Aldridge WN, Hoskin FCG, eds. Enzymes Hydrolysing Organophosporus Compounds. Chichester, UK: Ellis-Horwood; 1989: 202-13.
4. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
5. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-53.
6. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-35.
7. Watson AD, Berliner JA, Hama SY, La Du BN, Fault KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91.
8. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272: 13597-607.
9. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 95: 774-82.
10. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
11. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101: 1581-90.
12. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630-9.
13. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
14. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/aryiesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
16. Mackness MI, Patel B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
17. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalia J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334-6.
18. Blatter-Garin M-C, James RW, Dussoix P, Blanche H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99: 62-6.
19. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998; 423: 57-60.
20. Ruiz J, Blanche H, James RW, Blatter-Garin M-C, Vaise C, Charpentier G. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
21. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-8.
22. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257-60.
23. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. The 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-9.
24. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-73.
25. Herrmann SM, Blanche H, Poirier O, Arveiter D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996; 126: 299-304.
26. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98: 883-5.
27. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57: 69-73.
28. Lansbury AJ, Calto AJ, Carter AM, Bamford JM, Grant PJ. The paraoxonase glutamine-arginine polymorphism and cerebrovascular disease. Cardiovasc Dis 1997; 7: 353-6.
29. Sanghera DK, Saha N, Kamboh MI. The codon 55 polymorphism of the paraoxonase 1 gene is not associated with risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136: 217-23.
30. Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997; 349: 851-2.
31. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein K-45. Eur J Biochem 1993; 211: 871-9.
32. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40: 277-82.
33. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-9.
34. Pavkovic E, Simeon V, Reiner E, Sucic M, Lipovac V. Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders. Chem Biol Interact 1993; 87: 179-82.
35. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15: 89-95.
36. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol 1995; 15: 861-71.
37. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol 1997; 17: 1060-6.
38. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998; 213: 149-57.
39. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62: 36-44.
40. Hegele RA, Harris SB, Connelly PW, Hanley AJ, Tsui LC, Zinman B, et al. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin Genet 1998; 54: 394-9.
41. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 1998; 139: 131-6.
42. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, et al. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 3373-7.
43. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, et al. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet 1997; 350: 785.
44. Busch CP, Ramdath DD, Ramsewak S, Hegele RA. Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics (in press).
45. Barker DJP. The fetal and infant origins of disease. Eur J Clin Invest 1995; 25: 457-63.
46. Dhawan J. Coronary heart disease risks in Asian Indians. Curr Opin Lipidol 1996; 7: 196-8.
47. Stein CE, Fall CHD, Kumaran K, Osmond C, Cox V, Barker DJP. Fetal growth and coronary heart disease in South India. Lancet 1996; 384: 1269-73.
48. Dunger DB, Ong KKL, Huxtable SJ, Sherriff A, Woods KA, Ahmed ML, et al. Association of the INS VNTR with size at birth. Nat Genet 1998; 19: 98-100.